HEALTH OF WOMAN. 2019.1(137):92–95; doi 10.15574/HW.2019.137.92

Bysaha N. Yu.
SHEE «Uzhgorod national University»

Hypertensive disorders in pregnancy remain an important medical and social problem of public health and occur in about 12–24% of pregnancies. In the structure of the causes of maternal mortality preeclampsia of pregnant women for the past 10 years is mainly 3-4th place. Preeclampsia increases the risk of unwanted pregnancy outcomes not only for the mother, but also for the fetus. The indicator of perinatal mortality for this pathology varies within 10–30‰, perinatal morbidity – 463–780‰. Perinatal morbidity and mortality in preeclampsia are due to premature birth (30.0%), chronic hypoxia (40.0%), and intrauterine growth retardation of the fetus (30.0%).

Key words: pregnancy, preeclampsia, endothelium, delayed intrauterine growth of the fetus.

REFERENCES

1. Konkov DG, Protsepko AA. (2009). Endotelialnaya disfunktsiya v geneze nevyinashivaniya beremennosti. Problemy, dostizheniya i perspektivy razvitiya mediko-biologicheskih nauk i prakticheskogo zdravohraneniya 145;II:157–160.

2. Augusto Henriques Fulgencio Brandao, Marcelo Araujo Cabral. (2012). Endothelial function, uterine perfusion and central flow in pregnancies complicated by preeclampsia. Arq. Bras. Cardiol. 13; 99(4):931–935.

3. Wang Y, Gu Y, Zhang Y, Lewis DF. (2008). Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am. J. Obstet. Gynecol. 190 (3):817–824. https://doi.org/10.1016/j.ajog.2003.09.049; PMid:15042020

4. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. (2011). NICE Clinical Guidelines. National Collaborating Centre for Women’s and Children’s Health (UK). London, RCOG Press: 295.

5. Konkov DG. (2013). Caratteristiche prevenzione dei clinici manifesti-forme endoteliopatia gestazionale. Italian Science Review 8: 11–15.

6. Buger RH. (2008). The pharmacodynamics of L-arginine. J. Nutr. 137:1650S-1655S. https://doi.org/10.1093/jn/137.6.1650S; PMid:17513442

7. Hlybova SV, Tsirkin VI, Dvoryanskiy SA i dr. (2009). Soderzhanie arginina v syivorotke krovi pri fiziologicheskom i oslozhnennom techenii beremennosti. Ros. vestn. akushera-ginekologa 2: 4-7.

8. Chatterjee A, Catravas JD. (2008). Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol. 49 (4-6):134-140. https://doi.org/10.1016/j.vph.2008.06.008; PMid:18692595 PMCid:PMC2592563

9. Gilbert JS, Niland MJ, Knoblich P. (2008). Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev. Cardiovasc. Ther. 6(10): 1367-1377. https://doi.org/10.1586/14779072.6.10.1367; PMid:19018690 PMCid:PMC2650232

10. Golovchenko YuI, Treschinskaya MA. (2008). Obzor sovremennyih predstavleniy ob endotelialnoy disfunktsii. Cons. med. Ukr. 11:38-40.

11. Bryan NS, Bian K, Murad F. (2009). Discovery of the nitric oxide signaling pathway and targets for drug development. Frontiers in Bioscience 14:1-18. https://doi.org/10.2741/3228

12. Baylis C. (2008). Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol. 294:1-9. https://doi.org/10.1152/ajprenal.00424.2007; PMid:17928410

13. Babushkina AV. (2009). L-arginin s tochki zreniya dokazatelnoy meditsinyi. Ukr. Med. Chasopis 74 (HI/XII):43-48.

14. Facchinetti F, Saade GR, Neri I et al. (2009). L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy 26 (1):121-130. https://doi.org/10.1080/10641950601147994; PMid:17454224

15. Lezhenko HO, Reznichenko YuH. (2009). Zastosuvannia zamisnoi imunoterapii pry likuvanni ditei iz zatrymkoiu vnutrishnoutrobnoho rozvytku. Perynatologyia y pedyatrіya 1 (37): 95-98.

16. Stepaniuk AH, Hryb VD. (2008). Do pytannia shchodo zatrymky vnutrishnoutrobnoho rozvytku ploda. Zdorove zhenshchyny 4 (36):95-97.

17. Maziad AA, Schaa K, Bell EF, Dagle JM, Cooper M, Marazita ML, Murray JC. (2010). Role of polymorphic variants as genetic modulators of infection in neonatal sepsis. Pediatr. Res. 68 (4):323-329. https://doi.org/10.1203/PDR.0b013e3181e6a068; PMid:20463618 PMCid:PMC2940937

18. Chauhan M, McGuire W. (2008). Interleukin-6 (-174C) polymorphism and the risk of sepsis in very-lowbirth-weight infants: meta-analysis. Arch. Dis. Child. Fetal Neonatal Ed. 93:F427-429. https://doi.org/10.1136/adc.2007.134205; PMid:18375611

19. Schuurhof A, Janssen R, Groot H, Hodemaekers HM, Klerk A, Kimpen J, Bont L. (2011). Local interleukin-10 production during respiratory syncytial virus bronchiolitis ia associated with post-bronchiolitis wheeze. Respir. Res. 12:121. https://doi.org/10.1186/1465-9921-12-121; PMid:21910858 PMCid:PMC3179726

20. Hui L, Challis D. (2008). Diagnosis and management of fetal growth restriction: the role of fetal therapy. Best Pract. Res. Clin. Obstet. Gynaecol. 22 (1):139-158. https://doi.org/10.1016/j.bpobgyn.2007.06.004; PMid:17698415

21. Bose C, Van Marter LJ, Laughon M, O’Shea TM, Allred EN, Karna P et al. (2009). Fetal growth restriction and chronic lung disease among infants born before the 28^th week of gestation. Extremely Low Gestational Age Newborn Study Investigators. Pediatrics 124 (3):e450-458. https://doi.org/10.1542/peds.2008-3249; PMid:19706590 PMCid:PMC2891899